Phase II Study of Nitric Oxide Donor for Men With Increasing Prostate-specific Antigen Level After Surgery or Radiotherapy for Prostate Cancer
Authors:
- D. Robert SiemensDSD. Robert Siemens
- Jeremy P.W. HeatonJHJeremy P.W. Heaton
- Michael A. AdamsMAMichael A. Adams
- Jun KawakamiJKJun Kawakami
- Charles H. GrahamCGCharles H. Graham
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric OxideCancer Research, 2008
- Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide SignalingClinical Cancer Research, 2007
- Randomized Phase II Trial Comparing Nitroglycerin Plus Vinorelbine and Cisplatin With Vinorelbine and Cisplatin Alone in Previously Untreated Stage IIIB/IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapyCancer, 2004
- Nitric oxide‐mediated regulation of hypoxia‐induced B16F10 melanoma metastasisInternational Journal of Cancer, 2003
- Hypoxia Induced Resistance to Doxorubicin in Prostate Cancer Cells is Inhibited by Low Concentrations of Glyceryl TrinitrateJournal of Urology, 2003
- High‐dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinomaCancer, 2003
- SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMYJournal of Urology, 2001
- Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapySeminars in Oncology, 2001